BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24033280)

  • 1. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis.
    Kharfan-Dabaja MA; Hamadani M; Reljic T; Pyngolil R; Komrokji RS; Lancet JE; Fernandez HF; Djulbegovic B; Kumar A
    Br J Haematol; 2013 Nov; 163(3):315-25. PubMed ID: 24033280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
    Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
    Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
    Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
    Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
    Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
    J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
    Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis.
    Guo Y; Deng L; Qiao Y; Liu B
    Hematology; 2022 Dec; 27(1):53-64. PubMed ID: 34957930
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
    Castaigne S; Pautas C; Terré C; Raffoux E; Bordessoule D; Bastie JN; Legrand O; Thomas X; Turlure P; Reman O; de Revel T; Gastaud L; de Gunzburg N; Contentin N; Henry E; Marolleau JP; Aljijakli A; Rousselot P; Fenaux P; Preudhomme C; Chevret S; Dombret H;
    Lancet; 2012 Apr; 379(9825):1508-16. PubMed ID: 22482940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Immunol; 2021; 12():683595. PubMed ID: 34484181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
    Kell J
    Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
    Ashaye AO; Khankhel Z; Xu Y; Fahrbach K; Mokgokong R; Orme ME; Lang K; Cappelleri JC; Mamolo C
    Future Oncol; 2019 Feb; 15(6):663-681. PubMed ID: 30450960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
    Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
    J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
    Amadori S; Suciu S; Stasi R; Salih HR; Selleslag D; Muus P; De Fabritiis P; Venditti A; Ho AD; Lübbert M; Thomas X; Latagliata R; Halkes CJ; Falzetti F; Magro D; Guimaraes JE; Berneman Z; Specchia G; Karrasch M; Fazi P; Vignetti M; Willemze R; de Witte T; Marie JP
    J Clin Oncol; 2013 Dec; 31(35):4424-30. PubMed ID: 24127442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
    Fianchi L; Pagano L; Leoni F; Storti S; Voso MT; Valentini CG; Rutella S; Scardocci A; Caira M; Gianfaldoni G; Leone G
    Ann Oncol; 2008 Jan; 19(1):128-34. PubMed ID: 17906298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
    Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
    Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
    Burnett A; Cavenagh J; Russell N; Hills R; Kell J; Jones G; Nielsen OJ; Khwaja A; Thomas I; Clark R;
    Haematologica; 2016 Jun; 101(6):724-31. PubMed ID: 26921360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.